Publications
Stay up to date with our literature reviews which are curated by experts to feature the most important publications released each month. Explore our publications for access to concise summary slides for your own use.
Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD
Clin J Am Soc Nephrol. 2022; online ahead of print DOI: 10.2215/CJN.03790322
Dapagliflozin has been shown to reduce CKD progression and KRT requirement when added to standard therapy in patients with CKD in the DAPA-CKD trial. This analysis was designed to estimate the cost-effectiveness of dapagliflozin for the treatment of CKD from payer perspectives in the UK, Germany and Spain.
Dapagliflozin and New-Onset Type 2 Diabetes in Patients With Chronic Kidney Disease Or Heart Failure: Pooled Analysis of the DAPA-CKD and DAPA-HF Trials
Lancet Diabetes Endocrinol 2022;10:24–34 doi.org/10.1016/
Chronic kidney disease and heart failure are insulin resistant states associated with high incidence rates of diabetes. Rossing et al. carried out a two Phase 3, randomised, double-blind, placebo-controlled trials assessed the effect of dapagliflozin on new-onset type 2 diabetes, in a pooled analysis of data from 6,608 individuals.